Cargando…

Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review

OBJECTIVES: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, and type I interferon plays an important role in its pathogenesis. Anifrolumab is a new strategy for the treatment of systemic lupus erythematosus. It could antagonize the activity of all type 1 interferons by binding wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhihui, Cheng, Ruijuan, Liu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537685/
https://www.ncbi.nlm.nih.gov/pubmed/36211347
http://dx.doi.org/10.3389/fimmu.2022.996662
_version_ 1784803261129162752
author Liu, Zhihui
Cheng, Ruijuan
Liu, Yi
author_facet Liu, Zhihui
Cheng, Ruijuan
Liu, Yi
author_sort Liu, Zhihui
collection PubMed
description OBJECTIVES: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, and type I interferon plays an important role in its pathogenesis. Anifrolumab is a new strategy for the treatment of systemic lupus erythematosus. It could antagonize the activity of all type 1 interferons by binding with type I interferon receptor subunit 1. The aim of our study was to evaluate the safety of anifrolumab in patients with moderate to severe SLE (excluding patients with active severe lupus nephritis or central nervous system lupus). METHODS: Four databases (Embase, Cochrane, PubMed, Web of Science) were systematically searched from inception until December 2021 for randomized controlled trials (RCTs) evaluating the safety of anifrolumab versus placebo in SLE patients. Then, the incidence of adverse events in each study was aggregated using meta-analysis. RESULTS: A total of 1160 SLE patients from four RCTs were included in the analysis. Serious adverse events were less common in the anifrolumab group than in the placebo group (RR: 0.76, 95% CI: 0.59-0.98, p<0.03). The most common adverse events included upper respiratory tract infection (RR: 1.48, 95% CI: 1.13-1.94, P=0.004), nasopharyngitis (RR: 1.66, 95% CI: 1.25-2.20, P=0.0004), bronchitis (RR: 1.96, 95% CI: 1.32-2.92, P=0.0009), and herpes zoster (RR: 3.40, 95% CI: 1.90-6.07, P<0.0001). CONCLUSION: Anifrolumab is considered a well-tolerated option for the treatment of SLE patients with good safety. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com, identifier 202230054.
format Online
Article
Text
id pubmed-9537685
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95376852022-10-08 Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review Liu, Zhihui Cheng, Ruijuan Liu, Yi Front Immunol Immunology OBJECTIVES: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, and type I interferon plays an important role in its pathogenesis. Anifrolumab is a new strategy for the treatment of systemic lupus erythematosus. It could antagonize the activity of all type 1 interferons by binding with type I interferon receptor subunit 1. The aim of our study was to evaluate the safety of anifrolumab in patients with moderate to severe SLE (excluding patients with active severe lupus nephritis or central nervous system lupus). METHODS: Four databases (Embase, Cochrane, PubMed, Web of Science) were systematically searched from inception until December 2021 for randomized controlled trials (RCTs) evaluating the safety of anifrolumab versus placebo in SLE patients. Then, the incidence of adverse events in each study was aggregated using meta-analysis. RESULTS: A total of 1160 SLE patients from four RCTs were included in the analysis. Serious adverse events were less common in the anifrolumab group than in the placebo group (RR: 0.76, 95% CI: 0.59-0.98, p<0.03). The most common adverse events included upper respiratory tract infection (RR: 1.48, 95% CI: 1.13-1.94, P=0.004), nasopharyngitis (RR: 1.66, 95% CI: 1.25-2.20, P=0.0004), bronchitis (RR: 1.96, 95% CI: 1.32-2.92, P=0.0009), and herpes zoster (RR: 3.40, 95% CI: 1.90-6.07, P<0.0001). CONCLUSION: Anifrolumab is considered a well-tolerated option for the treatment of SLE patients with good safety. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com, identifier 202230054. Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9537685/ /pubmed/36211347 http://dx.doi.org/10.3389/fimmu.2022.996662 Text en Copyright © 2022 Liu, Cheng and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Liu, Zhihui
Cheng, Ruijuan
Liu, Yi
Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
title Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
title_full Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
title_fullStr Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
title_full_unstemmed Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
title_short Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
title_sort evaluation of anifrolumab safety in systemic lupus erythematosus: a meta-analysis and systematic review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537685/
https://www.ncbi.nlm.nih.gov/pubmed/36211347
http://dx.doi.org/10.3389/fimmu.2022.996662
work_keys_str_mv AT liuzhihui evaluationofanifrolumabsafetyinsystemiclupuserythematosusametaanalysisandsystematicreview
AT chengruijuan evaluationofanifrolumabsafetyinsystemiclupuserythematosusametaanalysisandsystematicreview
AT liuyi evaluationofanifrolumabsafetyinsystemiclupuserythematosusametaanalysisandsystematicreview